The three horizons
Horizon 1
SL6733 — Snowmaking additive
2026/27 EU lab pilots → 2027/28 first commercial seasons → 2028/29 multi-resort EU deployment. Targeting $14–29M ARR at 30% category penetration of the addressable European Alpine market.
Horizon 2
DS-100 & DS-400 — next-gen pipeline
DS-100 is a synthetic antifreeze glycoprotein (sAFGP) class designed by the AI engine and engineered to sit outside competing antifreeze-protein IP. DS-400 targets ice-rink IRI applications. Both ship through licensing, not direct distribution.
Horizon 3
Adjacent cold-chain verticals
Food texture (frozen desserts, IQF), biologic and vaccine cold chains, cell and tissue cryopreservation. Each vertical is entered through a strategic partner that holds the regulatory pathway and distribution; DeepSnow contributes the polymer IP under licence.
Platform
The AI discovery engine
The shared substrate that compounds across all three horizons. Each polymer made and assayed strengthens the next prediction. Each licence deal expands the assay dataset. Platform improvement is the multiplier.
Annual milestones, 2026 → 2030
| Year | Headline milestone | Pipeline state |
|---|---|---|
| 2026 | EU lab-pilot cohort signed; SnowLabs Italia incorporated; SL6733 polymer lot scale-up to 100 L. | SL6733: pilot. DS-100/400: in silico. |
| 2027 | First commercial SL6733 season (2027/28); first DS-100 candidates synthesised; DS-400 ice-rink LoI signed with chain operator. | SL6733: commercial. DS-100: wet lab. DS-400: lit-search. |
| 2028 | Multi-resort EU deployment; first non-EU SL6733 territory; first Horizon-3 strategic-partner conversation. | SL6733: scaling. DS-100: pilot. DS-400: wet lab. |
| 2029 | DS-100 first commercial licence; cold-chain platform agreement with food or biologic partner; expansion of AI discovery engine into a third polymer class. | SL6733: mature. DS-100: commercial. DS-400: pilot. |
| 2030 | Group platform run-rate: SL6733 mature, DS-100 scaling, DS-400 launched, Horizon-3 vertical generating first material licence revenue. Optionality for capital event evaluated by the board. |